IRCT2012123010279N2 IRCT 2013-01-12 Health Ministry Drug and Pharmacy General Management Saccharomyces boulardii's efficiency on hyperbilirubinemia Comparison of the efficiency of Saccharomyces boulardii on neonatal hyperbilirubinemia with placebo on late pereterm and term neonates 2012-07-20 anticipated 150 Complete https://irct.ir/trial/10742 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Patients were assigned randomly to the study or control group by the principal investigator. Randomization was performed by using sequential numbers generated at the computer center. One nurse who was not involved in the care of the infants prepared Saccharomyces boulardii or distilled water. She gave the prepared material without label to the nurse who was responsible for the infant’s care. The first investigator who randomized patients and ordered supplementation to the first nurse gave just only the patients' name to the second investigator for follow-up. Therefore, the only personnel who knew the infants’ group assignments were the first investigator and the first nurse, who were not involved in the care of the study infants. 3 Neonatal hyperbilirubinemia. Intervention 1: The study group received Saccharomyces boulardii (Reflor®, Biocodex, France, 50 mg/kg per dose twice daily) during phototherapy. Intervention 2: The control group received placebo (distilled water; 1 cc per dose twice daily) during phototherapy.